Compounded GLP-1 Medications: Cost, Availability, and What You Need to Know in 2025

Something significant happened in American healthcare over the past two years that most people outside the medical and pharmaceutical world barely noticed until it affected their wallets or their prescriptions. Compounded versions of GLP-1 receptor agonists — the injectable drugs behind semaglutide and tirzepatide — flooded the market during a prolonged shortage period, offering men access to medications like Ozempic and Mounjaro at a fraction of the brand-name cost. Now, in 2025, that landscape is shifting dramatically, and if you’re using or considering a compounded GLP-1, understanding what’s actually happening — scientifically, legally, and economically — could save you money and protect your health.

The numbers alone tell a striking story. Brand-name semaglutide (Wegovy, Ozempic) retails for roughly $900 to $1,400 per month without insurance. Tirzepatide (Mounjaro, Zepbound) runs similarly high. Compounded alternatives, produced by FDA-registered 503A and 503B compounding pharmacies, have been available at $150 to $500 per month — sometimes even less — creating an access point that millions of Americans walked through. A workshop convened by the National Institute of Diabetes and Digestive and Kidney Diseases in May 2025 specifically flagged compounded formulations as one of the key complicating factors in understanding real-world GLP-1 use, noting that medication shortages and the rise of compounding had created inconsistencies that even regulators were struggling to track. That workshop synthesis, published in the Annals of Internal Medicine, underscored how compounding had quietly become a defining feature of the GLP-1 story in the United States — not a footnote.

Why Compounded GLP-1s Exist and How the Shortage Created a Market

To understand where we are in 2025, you have to go back to 2022 and 2023, when Novo Nordisk and Eli Lilly simply could not manufacture enough semaglutide and tirzepatide to meet exploding demand. The FDA placed both drugs on its official drug shortage list, and under federal law — specifically Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act — compounding pharmacies are permitted to prepare copies of drugs that appear on the shortage list. That legal window opened the floodgates.

Compounding pharmacies, ranging from small local operations to large outsourcing facilities, began producing semaglutide and tirzepatide in injectable and oral forms. Telehealth companies built entire business models around prescribing these compounded versions, often pairing them with remote physician consultations, nutrition coaching, and ongoing monitoring. For men who couldn’t afford $1,000+ per month or whose insurance flatly refused to cover weight-loss medications, compounding became the only realistic path to access.

The FDA, however, began removing semaglutide from the shortage list in late 2024 and moved to remove tirzepatide in early 2025, a decision that triggered significant legal battles. Several compounding pharmacy trade associations sued the FDA, arguing the shortage was not truly resolved at the patient level even if manufacturing capacity had improved. Courts issued temporary stays in some cases, creating a patchwork of enforcement that left many compounding pharmacies — and their patients — in legal limbo. As of mid-2025, enforcement has been selective and evolving, but the clear regulatory trajectory is toward limiting compounded GLP-1 availability over time.

What does this mean practically? If you’re currently using a compounded GLP-1 and it’s working for you, you likely still have access — but that access is less certain than it was twelve months ago. The men most at risk are those using telehealth platforms that relied entirely on compounded semaglutide or tirzepatide as their core product. Some of these platforms have already pivoted to brand-name prescriptions, which means sticker shock for patients who weren’t prepared.

The Real Cost-Effectiveness Question Behind the Price Tags

The conversation about GLP-1 costs goes far deeper than the monthly sticker price. A comprehensive systematic review published in Clinical Drug Investigation in 2026 — analyzing 142 long-term health economic evaluations of newer antidiabetic drugs including tirzepatide — found that 81% of cost-effectiveness analyses concluded these medications were cost-effective compared to conventional therapies, when evaluated over a lifetime horizon and accounting for cardiovascular and renal benefits. The review by Li, Smith, Marra and colleagues noted that recently introduced agents like tirzepatide were only considered cost-effective at willingness-to-pay thresholds of $100,000 to $150,000 per quality-adjusted life year, or following substantial price reductions.

That’s a critical distinction. A drug can be cost-effective in a health economics model — meaning it delivers enough long-term benefit to justify its cost — while still being completely unaffordable for the individual paying out of pocket right now. These two realities exist simultaneously, and they explain why compounding became so consequential. When a medication has a strong evidence base and delivers measurable long-term health benefits but costs $1,200 per month without insurance, the compounded version at $250 per month isn’t just a bargain — for many men, it’s the difference between using the medication or not using it at all.

The same systematic review highlighted that in lower-income countries, GLP-1 receptor agonists and newer antidiabetic drugs were generally not considered cost-effective because willingness-to-pay thresholds were far lower. Thailand, used as a case study, had thresholds of just $4,336 to $5,310 per quality-adjusted life year — a fraction of what U.S. health economists use as benchmarks. This global disparity matters for American men too, because it illustrates how pricing is not fundamentally tied to manufacturing cost or scientific value — it’s tied to what a given healthcare system is structured to pay. Compounding, in this context, represents a kind of market correction that the healthcare system wasn’t designed to handle gracefully.

Insurance coverage for GLP-1 medications remains frustratingly inconsistent. The NIDDK workshop noted that coverage decisions across Medicare, Medicaid, and private payers are heterogeneous and have shifted over time, making it difficult for patients to plan or predict their costs. Medicare Part D now covers semaglutide for cardiovascular risk reduction in certain patients following the SELECT trial results, but coverage for obesity as a primary indication remains limited. Private insurers vary enormously — some cover Wegovy or Zepbound with prior authorization; many do not. This patchwork means that even men who might qualify for GLP-1 therapy on clinical grounds face a lottery of whether their specific plan will pay for it.

What to Look For — and Watch Out For — If You’re Navigating This Market

If you’re currently using or considering a compounded GLP-1 medication, the single most important factor is the pharmacy’s regulatory status. Legitimate compounding pharmacies operate under state pharmacy board oversight and must comply with FDA regulations. Larger 503B outsourcing facilities are subject to more rigorous federal inspections. The red flags are clear: any pharmacy or telehealth platform selling semaglutide or tirzepatide without a valid prescription, making unverified purity or potency claims, or pricing suspiciously below market rates for even compounded versions should be treated with significant skepticism. The FDA has issued multiple warning letters to compounders selling adulterated or mislabeled GLP-1 products, and in some documented cases, independent testing has found significant discrepancies in drug concentration.

The NIDDK workshop specifically called out the challenges that compounded formulations create for real-world data collection — because when patients are using compounded products, the dose, formulation, and adherence patterns are often not captured accurately in electronic health records or insurance claims. This is a research problem, but it’s also a patient safety signal. If your use isn’t being tracked or monitored properly, neither are your outcomes.

On the practical side, men who are currently on compounded GLP-1 medications and seeing good results should be having an active conversation with their prescribing physician about transition planning. This means understanding what brand-name alternatives might be available, exploring manufacturer savings programs — both Novo Nordisk and Eli Lilly have patient assistance programs and savings cards that can bring costs down substantially for eligible patients — and considering whether your insurance situation might change with open enrollment. Some men will find that the total cost difference between a well-discounted brand-name prescription and a compounded version has narrowed meaningfully in 2025.

It’s also worth being clear-eyed about what GLP-1 medications do and don’t do on their own. These drugs are powerful metabolic tools, particularly for men dealing with significant excess weight, insulin resistance, or metabolic syndrome. But the research consistently shows that outcomes are best when medication is paired with meaningful lifestyle behavior — adequate protein intake to preserve muscle mass during weight loss, resistance training, sleep optimization, and stress management. Men who use GLP-1 medications as a crutch without building those underlying habits tend to regain weight when they discontinue. Men who use the medication as a catalyst to build better habits tend to maintain more of their results. That distinction isn’t just motivational — it has real implications for whether the cost of any GLP-1 therapy, compounded or brand-name, is actually worth it for you personally.

The Takeaway

The compounded GLP-1 market in 2025 exists because brand-name medications remain expensive and insurance coverage remains unreliable — and because a shortage opened a legal door that a lot of men walked through. That door is narrowing. Regulatory enforcement is tightening, shortages are being officially resolved even if access frustrations remain real, and the legal battles over compounding rights are still working through the courts. For men currently using compounded semaglutide or tirzepatide, now is the time to get informed, not reactive. Know your pharmacy’s credentials, have a transition plan if your current source becomes unavailable, and anchor your health strategy to the fundamentals that no regulatory change can take away. GLP-1 medications, at their best, are a bridge — the destination is a body and a metabolism that works better, built on nutrition, training, and consistent daily habits that compound just as reliably as any drug.